This company listing is no longer active
Longboard Pharmaceuticals (LBPH) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LBPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Longboard Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.98 |
| 52 Week High | US$60.03 |
| 52 Week Low | US$3.82 |
| Beta | 1.09 |
| 1 Month Change | 0.49% |
| 3 Month Change | 76.36% |
| 1 Year Change | 1,414.65% |
| 3 Year Change | 1,042.48% |
| 5 Year Change | n/a |
| Change since IPO | 260.24% |
Recent News & Updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Summary Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction data, but faces competition and safety concerns; Lundbeck aims for a 2028 launch with peak sales potential of $1.5-$2 billion. Longboard's management, led by CEO Kevin Lind, has a strong track record in securing lucrative M&A deals, making them a team to watch. Investing in Longboard shares now holds little value post-agreement; future opportunities may arise from Lind's next ventures or new spinouts. Read the full article on Seeking AlphaMy Strategy For Longboard Pharmaceuticals After Its Big Run
Summary Longboard Pharma saw significant growth after the initial spike, with potential catalysts in the future. LBPH develops neurological medicines, with a strong pedigree from Arena Pharmaceuticals. Lead drug Bexicaserin has shown promising data, with upcoming catalysts and potential for sustained response. Read the full article on Seeking AlphaRecent updates
Shareholder Returns
| LBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.1% | -2.0% | 0.7% |
| 1Y | 1,414.6% | 44.4% | 20.6% |
Return vs Industry: LBPH exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: LBPH exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| LBPH volatility | |
|---|---|
| LBPH Average Weekly Movement | 17.0% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LBPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LBPH's weekly volatility has decreased from 46% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 50 | Kevin Lind | www.longboardpharma.com |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases.
Longboard Pharmaceuticals, Inc. Fundamentals Summary
| LBPH fundamental statistics | |
|---|---|
| Market cap | US$2.34b |
| Earnings (TTM) | -US$76.34m |
| Revenue (TTM) | n/a |
Is LBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.34m |
| Earnings | -US$76.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LBPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/02 18:07 |
| End of Day Share Price | 2024/11/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longboard Pharmaceuticals, Inc. is covered by 2 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Citigroup Inc |
| Yatin Suneja | Guggenheim Securities, LLC |